Aquestive Therapeutics (NASDAQ:AQST) Trading Up 6.5% – Here’s Why

Aquestive Therapeutics, Inc. (NASDAQ:AQST)’s stock price rose 6.5% during trading on Monday . The company traded as high as $5.82 and last traded at $5.74. Approximately 670,326 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 1,995,991 shares. The stock had previously closed at $5.39.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Piper Sandler upped their price objective on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Oppenheimer raised their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Zacks Research raised shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.00.

Aquestive Therapeutics Price Performance

The business’s 50-day simple moving average is $5.99 and its 200-day simple moving average is $4.38. The company has a market cap of $692.35 million, a price-to-earnings ratio of -7.98 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million during the quarter, compared to analysts’ expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 10,000 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total transaction of $70,000.00. Following the sale, the insider owned 268,323 shares of the company’s stock, valued at $1,878,261. This represents a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Barber sold 91,343 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $550,798.29. Following the completion of the sale, the chief executive officer owned 923,430 shares in the company, valued at $5,568,282.90. This represents a 9.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 276,770 shares of company stock valued at $1,692,203 over the last 90 days. Company insiders own 7.85% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $3,354,000. Mercer Global Advisors Inc. ADV bought a new position in Aquestive Therapeutics in the third quarter valued at $84,000. Lido Advisors LLC purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth about $167,000. Brevan Howard Capital Management LP purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $189,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Aquestive Therapeutics in the third quarter worth about $162,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.